Evidence map›Paper›PMID 31103340›Full record

ArticleClinical genitourinary cancer2019

Serum Proteomics on the Basis of Discovery of Predictive Biomarkers of Response to Androgen Deprivation Therapy in Advanced Prostate Cancer.

Manish Kohli, Ann L Oberg, Douglas W Mahoney, Shaun M Riska, Robert Sherwood, Yuzi Zhang, Roman M Zenka, Deepak Sahasrabudhe, Rui Qin, Sheng Zhang

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Clinical genitourinary cancer, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
0.7field-weighted citation impact, top 35% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 18 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Review
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 5 institutions in 1 country.

Manish KohliDepartment of Medical Oncology, Mayo Clinic, Rochester, MN. Electronic address: Manish.Kohli@moffitt.org.
Ann L ObergDepartment of Health Sciences Research, Mayo Clinic, Rochester, MN.
Douglas W MahoneyDepartment of Health Sciences Research, Mayo Clinic, Rochester, MN.
Shaun M RiskaDepartment of Health Sciences Research, Mayo Clinic, Rochester, MN.
Robert SherwoodInstitute for Biotechnology and Life Science Technologies, Cornell University, Ithaca, NY.
Yuzi ZhangDepartment of Health Sciences Research, Mayo Clinic, Rochester, MN.
Roman M ZenkaProteomcis Core, Mayo Clinic, Rochester, MN.
Deepak SahasrabudheDepartment of Medicine, University of Rochester, NY.
Rui QinClinical Biostatistics, Janssen Pharmaceuticals, Raritan, NJ.
Sheng ZhangInstitute for Biotechnology and Life Science Technologies, Cornell University, Ithaca, NY. Electronic address: sz14@cornell.edu.
Mayo Clinic in Florida · USCornell University · USJanssen (United States) · USMayo Clinic in Arizona · USUniversity of Rochester · US

Funding

Acquisition of a Hybrid Quadrupole, Ion Mobility Separation, Orthogonal AcceleratS10RR025449 · NCRR · CORNELL UNIVERSITY · PI ZHANG, SHENG · 2009 to 2009
$500k
A Proteomics Approach for Identifying Predictive Factors to Androgen DeprivationR21CA133536 · NCI · MAYO CLINIC ROCHESTER · PI KOHLI, MANISH · 2009 to 2010
$392k
NCI NIH HHS R21 CA133536NCRR NIH HHS S10 RR025449
6 · The paper itself

Abstract

backgroundWe investigated the serum proteome of hormone-sensitive prostate cancer patients to determine candidate biomarkers associated with androgen deprivation therapy (ADT) efficacy. PATIENTS AND

methodsSerum proteomes generated using isobaric mass tags for relative and absolute quantitation were analyzed using reverse-phase liquid chromatography coupled to tandem mass spectrometry. The advanced hormone-sensitive prostate cancer cohorts studied were: (1) untreated "paired" pre-ADT and 4-month post-ADT hormone-sensitive patients (n = 15); (2) "early ADT failure" patients (n = 10) in whom ADT treatment failed within a short period of time; and (3) "late ADT failure" patients (n = 10) in whom ADT treatment failed after a prolonged response time. Differential abundance was assessed, and ingenuity pathway analysis (IPA) was used to identify interaction networks in selected candidates from these comparisons.

resultsBetween "post-ADT" and combined "early" and "late" ADT failure groups 149 differentially detected candidates were observed, and between "early" and "late" ADT failure groups 98 candidates were observed; 47 candidates were common in both comparisons. IPA network enrichment analysis of the 47 candidates identified 3 interaction networks (P < .01) including 17-β-estradiol, nuclear factor kappa-light-chain enhancer of activated B cells complex, and P38 mitogen-activated protein kinases as pathways with potential markers of response to ADT.

conclusionA global proteomic analysis identified pathways with markers of ADT response, which will need validation in independent data sets.

Indexed as

AgedAged, 80 and overAndrogen AntagonistsBiomarkersChromatography, LiquidHumansMaleMiddle AgedProstatic NeoplasmsProtein Interaction MapsProteomicsTandem Mass SpectrometryTreatment OutcomeAndrogen AntagonistsBiomarkersHormonal therapyPredictive factorsProstate cancerProteomicsSerum

Identifiers

PMID31103340
PMCPMC6660363
OpenAlexW2922260889

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.